Mr. Pierre Montanaro reports

DEVONIAN HEALTH GROUP ANNOUNCES PRESENTATION OF THYKAMINE(TM) EFFICACY RESULTS IN ATOPIC DERMATITIS AT THE WORLD CONGRESS OF DERMATOLOGY AND PROVIDES THYKAMINE(TM) CLINICAL DEVELOPMENT PROGRAM UPDATE.

Devonian Health Group Inc.'s results from phase 2 clinical study in mild-to-moderate atopic dermatitis (AD) will be presented at the upcoming 25th World Congress of Dermatology (WCD) to be held in Singapore from July 3 to 8. Results from the study will be made available on Devonian's website following the poster presentation at WCD by Dr. Charles Lynde (Associate Professor, University of Toronto, Department of Medicine) at https://www.groupedevonian.com/investor-center/corporate-presentation.

Poster: Phase 2 trial of a Novel Botanical Topical Anti-Inflammatory Drug, in adults with Mild-to-Moderate Atopic Dermatitis. This poster summarizes results from the phase 2 clinical study in adult patients with mild-to-moderate atopic dermatitis. In the study, the efficacy of Thykamine(TM) cream was comparable to other non-steroidal topical therapies approved for the treatment of mild-to-moderate AD, while demonstrating a favorable safety and tolerability profile.

Thykamine(TM) Clinical Development Program Update

Devonian also provided an update on its Thykamine(TM) program activities in advance of the WCD Meeting. To support the clinical program of Thykamine(TM), the company is establishing its final formulation manufacturing activities in a leading global contract development and manufacturing. The transfer and validation process should be completed within the next months. Devonian will then, as a priority, file to regulatory agencies a phase 2/3 protocol in pediatric patient population with mild-to-moderate atopic dermatitis. As second and third priorities, the corporation expects to file a phase2 clinical study protocol in radiodermatitis associated to radiotherapy and a phase 2 clinical study in Hand and Foot Syndrome associated to chemotherapy.

"We are thrilled to see the vast potential of Thykamine(TM) as a novel treatment option for pediatric patients with atopic dermatitis and other skin inflammatory conditions" commented Mr Pierre Montanaro, President and Chief Executive Officer of the Corporation. "While our focus is on pediatric patient population suffering of Atopic dermatitis, there are clearly unmet medical needs for cancer patients with chemotherapy-related Hand and Foot Syndrome as well as for patients with radiotherapy-related radiodermatitis1. We believe that Thykamine(TM) could be an effective therapeutic for these physical skin changes associated to cancer therapies and help improve patients Quality of Life" added Mr. Montanaro.

About Devonian

Devonian Health Group Inc. (Devonian)is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.

Devonian is listed on the TSX Venture Exchange (TSXV: GSD) as well as the OTCQB Venture Exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com

Reference Pembroke M, Bradley J, and Nemeth LS, Breast Cancer Survivors Unmet Needs After Completion of Radiation Therapy Treatment. Oncol Nurs Forum. 2020 Jul 1;47(4):436-445.

We seek Safe Harbor.